Approved & therapeutic
Pramlintide
Symlin
Pramlintide is a synthetic analog of the pancreatic hormone amylin, approved in the US as an adjunct to mealtime insulin in type 1 or type 2 diabetes for people who have not reached glycemic targets on optimized insulin alone. It carries a boxed warning for severe hypoglycemia. It is an amylin analog, not an incretin. All US formulations have been discontinued by the manufacturer and no generic exists, so it is approved but not obtainable in the US.
- Status
- Pramlintide is approved by the U.S. FDA and has official prescribing information.
- Evidence
- Approved labeling. Official prescribing information exists, based on clinical trials in people.
- Half-life
- Approximately 48 minutes in healthy human subjects (SYMLIN label, Clinical Pharmacology).
- How it's taken
- Subcutaneous injection into the abdomen or thigh immediately before major meals; not into the arm, where absorption is variable. Given as a separate injection from insulin, at a site distinct from the insulin injection site.
- Mechanism
- Metabolic (non-incretin)
- Pathways
- Amylin
How Pramlintide works
Pramlintide is a stabilized analog of human amylin, a hormone co-secreted with insulin by pancreatic beta cells and deficient in insulin-requiring diabetes. It slows gastric emptying, suppresses postprandial glucagon secretion, and increases satiety, together blunting the post-meal glucose rise.
What research has looked at
- Primary endpoint in all five pivotal trials was HbA1c change. Placebo-subtracted reduction at 6 months was -0.25 to -0.34 percent in three type 1 diabetes trials and -0.30 to -0.34 percent in two type 2 diabetes trials. The effect is statistically real but small.
- Reduced postprandial glucose excursions, consistent with the labeled pharmacology of slowed gastric emptying and suppressed postprandial glucagon.
- Secondary and descriptive endpoint: mean body weight fell 0.8 to 1.6 kg on pramlintide versus a 0.1 to 0.8 kg gain on placebo, in contrast to the weight gain typical of intensified insulin therapy. Weight loss is NOT an approved indication for pramlintide and the FDA label makes no weight claim.
- Secondary and descriptive endpoint: mealtime insulin dose at 6 months changed about -7.1 percent in type 1 diabetes (versus -2.4 percent on placebo) and -3.0 percent for rapid or short-acting insulin in type 2 diabetes (versus +6.5 percent on placebo). This is a small placebo-corrected difference and is separate from the mandatory insulin reduction required at initiation.
Evidence level: Approved labeling. Official prescribing information exists, based on clinical trials in people. These are areas studied or reported, not promised effects.
Reported side effects and risks
- Boxed warning: use with insulin increases the risk of severe hypoglycemia, particularly in type 1 diabetes; when severe hypoglycemia occurs it is seen within 3 hours of an injection, and it can cause serious injury if it happens while driving or operating heavy machinery. Appropriate patient selection, careful instruction, and insulin dose reduction are critical to reducing this risk.
- Contraindicated in hypoglycemia unawareness, in confirmed gastroparesis, and after serious hypersensitivity to pramlintide or any of its ingredients.
- Label-restricted patient selection: not to be considered in patients with poor compliance with insulin therapy or blood glucose monitoring, HbA1c above 9 percent, recurrent severe hypoglycemia requiring assistance within the past 6 months, hypoglycemia unawareness, confirmed gastroparesis, or who require gastrointestinal motility stimulators. Not for pediatric patients. Prescribe cautiously with visual or dexterity impairment.
- Must never be mixed with insulin in the same syringe (mixing alters the pharmacokinetics of both); pens must never be shared between patients even with a new needle, because of blood-borne pathogen transmission risk.
- Delayed gastric emptying can slow or reduce absorption of concomitant oral medications. Drugs requiring rapid onset or a threshold concentration (analgesics, antibiotics, oral contraceptives) should be given at least 1 hour before or 2 hours after the pramlintide injection.
- Not recommended with drugs that alter gastrointestinal motility (for example anticholinergics such as atropine) or that slow intestinal absorption of nutrients (for example alpha-glucosidase inhibitors).
- Most common adverse reactions were nausea, vomiting, anorexia and headache. Local allergic reactions at injection sites (erythema, edema, pruritus) have been reported, usually resolving over days to weeks.
- Availability: all US formulations are listed as Discontinued in Drugs@FDA and no generic pramlintide exists. The approval was discontinued, not withdrawn for safety or effectiveness, but the product is not obtainable in the US. The labeled content is still the 2019 revision, so it will not reflect any class-wide labeling change after that date.
Sources
- PubMed research on Pramlintide · NIH · National Library of Medicine
- DrugBank record for Pramlintide · DrugBank
- Active clinical trials for Pramlintide · U.S. National Library of Medicine
Track Pramlintide in Peptide Vault
Log every dose, set reminders on your own schedule, rotate injection sites and keep your vials organized. Peptide Vault records what you enter. It doesn't recommend compounds or doses. iPhone, on-device.
Related compounds
Pramlintide FAQ
What is Pramlintide?
Pramlintide is a synthetic analog of the pancreatic hormone amylin, approved in the US as an adjunct to mealtime insulin in type 1 or type 2 diabetes for people who have not reached glycemic targets on optimized insulin alone. It carries a boxed warning for severe hypoglycemia. It is an amylin analog, not an incretin. All US formulations have been discontinued by the manufacturer and no generic exists, so it is approved but not obtainable in the US.
How does Pramlintide work?
Pramlintide is a stabilized analog of human amylin, a hormone co-secreted with insulin by pancreatic beta cells and deficient in insulin-requiring diabetes. It slows gastric emptying, suppresses postprandial glucagon secretion, and increases satiety, together blunting the post-meal glucose rise.
Is Pramlintide FDA approved?
Yes. Pramlintide is approved by the U.S. FDA and has official prescribing information. Evidence level: approved labeling. Official prescribing information exists, based on clinical trials in people.
What is the half-life of Pramlintide?
Reported half-life: Approximately 48 minutes in healthy human subjects (SYMLIN label, Clinical Pharmacology).
How is Pramlintide taken?
Subcutaneous injection into the abdomen or thigh immediately before major meals; not into the arm, where absorption is variable. Given as a separate injection from insulin, at a site distinct from the insulin injection site.
What side effects have been reported with Pramlintide?
Reported in the sources: Boxed warning: use with insulin increases the risk of severe hypoglycemia, particularly in type 1 diabetes; when severe hypoglycemia occurs it is seen within 3 hours of an injection, and it can cause serious injury if it happens while driving or operating heavy machinery. Appropriate patient selection, careful instruction, and insulin dose reduction are critical to reducing this risk; Contraindicated in hypoglycemia unawareness, in confirmed gastroparesis, and after serious hypersensitivity to pramlintide or any of its ingredients; Label-restricted patient selection: not to be considered in patients with poor compliance with insulin therapy or blood glucose monitoring, HbA1c above 9 percent, recurrent severe hypoglycemia requiring assistance within the past 6 months, hypoglycemia unawareness, confirmed gastroparesis, or who require gastrointestinal motility stimulators. Not for pediatric patients. Prescribe cautiously with visual or dexterity impairment; Must never be mixed with insulin in the same syringe (mixing alters the pharmacokinetics of both); pens must never be shared between patients even with a new needle, because of blood-borne pathogen transmission risk; Delayed gastric emptying can slow or reduce absorption of concomitant oral medications. Drugs requiring rapid onset or a threshold concentration (analgesics, antibiotics, oral contraceptives) should be given at least 1 hour before or 2 hours after the pramlintide injection; Not recommended with drugs that alter gastrointestinal motility (for example anticholinergics such as atropine) or that slow intestinal absorption of nutrients (for example alpha-glucosidase inhibitors); Most common adverse reactions were nausea, vomiting, anorexia and headache. Local allergic reactions at injection sites (erythema, edema, pruritus) have been reported, usually resolving over days to weeks; Availability: all US formulations are listed as Discontinued in Drugs@FDA and no generic pramlintide exists. The approval was discontinued, not withdrawn for safety or effectiveness, but the product is not obtainable in the US. The labeled content is still the 2019 revision, so it will not reflect any class-wide labeling change after that date.
Educational summary compiled from the sources listed above. Not medical advice. Peptide Vault does not sell, source or recommend any compound. Talk to a qualified clinician before starting or changing anything.